Actively Recruiting

Phase Not Applicable
Age: 55Years +
All Genders
ID04796545

Post-marketing Clinical Study of the SING IMT System Model NG SI IMT 3X in Patients With End-stage Age-related Macular Degeneration and Central Vision Loss

Led by VisionCare, Inc. · Updated on 2026-02-10

76

Participants Needed

13

Research Sites

95 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating the safety and effectiveness of the SING IMT (Smaller Incision New Generation Implantable Miniature Telescope) 3X implant to improve vision in patients aged 55 years and older with central vision impairment caused by end-stage Age-related Macular Degeneration (AMD). This is a prospective, multicenter, open-label study where all eligible patients receive the implant and are followed for one year. The study aims to determine how well the device works and its safety during this period. Participants who qualify will have the SING IMT 3X device implanted during routine cataract surgery. Eligibility is confirmed by testing vision improvement with an external telescope simulator before surgery. After implantation, patients will attend 6 to 10 vision training sessions with a low-vision specialist to help adapt to the device. Surgeons will also assess the usability and satisfaction of the implant during the study. Throughout the 12-month follow-up, participants will have regular eye exams to monitor vision and eye health in both eyes. The study will track any surgical complications, adverse events, and medication use from the start to the end of the study. Researchers will measure improvements in visual acuity and the safety of the implant system, including the delivery method used during surgery.

CONDITIONS

Brief Title

Post-market Clinical Investigation of the SING IMT System, Model NG SI IMT 3X in Patients With End-stage Age-related Macular Degeneration

Who Can Participate

Age: 55Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Be 55 years of age or older.
  • Have retinal findings of geographic atrophy or disciform scar with foveal involvement as shown by fluorescein angiography or OCT.
  • Have evidence of cataract.
  • Have best-corrected distance visual acuity no better than 20/80 and no worse than 20/800 in both eyes.
  • Have adequate peripheral vision in the eye not scheduled for surgery.
  • Achieve at least a five-letter improvement on the ETDRS chart in the eye scheduled for surgery using the 2.8X external telescope simulator.
  • Have an anterior chamber depth of at least 2.5 mm in the eye scheduled for surgery.
  • Be willing to participate in post-operative training for the implant.
  • Review and sign the informed consent form prior to study procedures.
  • Have adequate understanding of the local language and willingness to comply with study requirements.
Not Eligible

You will not qualify if you...

  • Evidence of active choroidal neovascularization or treatment for CNV within the past six months.
  • Any eye disease that compromises peripheral vision in the fellow eye.
  • History of steroid-responsive intraocular pressure rise, uncontrolled glaucoma, or preoperative IOP over 22 mm Hg.
  • Presence of corneal guttata.
  • Known sensitivity to post-operative medications.
  • Significant communication impairment or severe neurological disorders.
  • Previous intraocular or corneal surgery in the operative eye.
  • Ocular condition that predisposes to eye rubbing.
  • Ophthalmic surgery within 30 days before implant surgery.
  • Specific eye measurements outside set limits, including myopia >6.0 D, hyperopia >4.0 D, axial length <21 mm, endothelial cell density <1600 cells/mm², or narrow angle.
  • Inflammatory ocular disease.
  • Corneal dystrophies including guttata.
  • Zonular weakness or instability of the lens.
  • Diabetic retinopathy.
  • Untreated retinal tears.
  • Retinal vascular disease.
  • Optic nerve disease.
  • History of retinal detachment.
  • Retinitis pigmentosa.
  • Intraocular tumor.
  • Use of any investigational product within 30 days before enrollment or participation in another study during this trial.
  • Employment or close relation to the study sponsor or research organization.
  • Any condition or situation that may increase risk or interfere with study participation as judged by the investigator.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Surgery and Immediate Post-operative Care

Duration - Day of surgery plus immediate recovery

Participants undergo outpatient surgery to implant the SING IMT System during routine cataract surgery, followed by immediate post-operative care including usability and satisfaction assessments by the surgeon.

1 surgery visit and immediate post-operative assessments

Post-operative Follow-up

Duration - Up to 12 months

Participants undergo ophthalmic evaluations in both eyes at regular intervals and complete vision training with a low vision specialist.

Regular ophthalmic visits plus 6 to 10 vision training visits

Trial Site Locations

Total: 13 locations

1

UZ Brussel

Brussels, Belgium

Actively Recruiting

2

Centre d'Ophtalmologie Paradis-Monticelli

Marseille, France

Actively Recruiting

3

Hélios Ophtalmologie, Saint-Jean-de-Luz

Saint-Jean-de-Luz, France

Actively Recruiting

4

CHRU de Strasbourg

Strasbourg, France

Actively Recruiting

5

Augenklinik Städtisches Klinikum Karlsruhe

Karlsruhe, Germany

Terminated

6

Universitätsklinikum Münster Klinik für Augenheilkunde

Münster, Germany

Actively Recruiting

7

Mater Misericordiae University Hospital

Dublin, Ireland

Actively Recruiting

8

Università degli Studi di Napoli Federico II

Naples, Italy

Actively Recruiting

9

Fondazione Policlinico Universitario Agostino Gemelli

Roma, Italy

Actively Recruiting

10

VISSUM

Alicante, Spain

Actively Recruiting

11

Institut OMIQ

Barcelona, Spain

Actively Recruiting

12

Hospital Universitario La Luz - Quirónsalud

Madrid, Spain

Actively Recruiting

13

Royal Victoria Hospital Belfast Health & Social Care Trust

Belfast, United Kingdom

Actively Recruiting

Loading map...

Research Team

A

Anne Roller, PhD

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

OTHER

Number of Arms

1

Similar Trials

A Randomized Double-masked, Multicenter, 3-arm, Pivotal Phas...

Macular Degeneration

Actively Recruiting

30 locations

A Randomized, Double-Masked, Multicenter Study Comparing the...

Macular Degeneration

Actively Recruiting

9 locations

A Phase 3/4 Multicenter Study Assessing Safety of Intravitre...

Geographic Atrophy

Actively Recruiting

16 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here